Drug Trial Radar · NCT02347657
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
Last checked: Nov 19, 2026Latest source record: Jun 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
510
Actual
Start
Jan 2015
Primary completion
Jan 20, 2017
Study completion Jan 20, 2017
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Jan 27, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, double blind, placebo controlled, parallel group, multicenter study in people with cystic fibrosis (CF) who are homozygous for the F508del CF transmembrane conductance regulator (CFTR) gene mutation.
Conditions
- Cystic Fibrosis
Interventions
VX-661 Plus Ivacaftor CombinationDrug
FDC tablet, oral use
IvacaftorDrug
Tablet, oral use
VX-661 Plus Ivacaftor Combination PlaceboDrug
FDC tablet, oral use
Ivacaftor placeboDrug
Tablet, oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline (Day 1) in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24Time frame: Day 1, Through Week 24
Locations
74 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Little Rock, Arkansas
Site not named
Long Beach, California
Site not named
Denver, Colorado
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
Chicago, Illinois
Site not named
Peoria, Illinois
Site not named
Boston, Massachusetts
Site not named
Minneapolis, Minnesota
Site not named
St Louis, Missouri
Site not named
Manchester, New Hampshire
Site not named
Long Branch, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Albany, New York
Site not named
Buffalo, New York
Site not named
New Hyde Park, New York
Site not named
Rochester, New York
Site not named
Syracuse, New York
Site not named
Akron, Ohio
Site not named
Columbus, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Charleston, South Carolina
Site not named
Sioux Falls, South Dakota
Site not named
Fort Worth, Texas
Site not named
Tyler, Texas
Site not named
Seattle, Washington
Site not named
Milwaukee, Wisconsin
Site not named
Calgary, Alberta, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Halifax, Nova Scotia, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Copenhagen O, Denmark
Site not named
Marseille, Bouches-du-Rhone, France
Site not named
Roscoff, Finistere, France
Site not named
Bordeaux, Girande, France
Site not named
Lille, Nord, France
Site not named
Paris, Paris, France
Site not named
Pierre-Bénite, Rhone, France
Site not named
Berlin, Germany
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.